REGISTER BY OCTOBER 30 TO SAVE UP TO $900


5th Annual

Ophthalmic Drug Delivery Summit

Advancing Safe, Efficacious & Long-Lasting Delivery to the Eye

January 19-21, 2027 | San Francisco, CA

Advancing Novel, Durable, & Effective Ocular Drug Delivery Systems Whilst Improving Patient Adherence & Overcoming Regulatory Hurdles to Address Critical Unmet Medical Needs



Your Expert Speakers Include:



Hemant Khanna
Ophthalmology Strategy Lead
Astellas



Stephen Poor
Head of Translational Medicine
Apellis



Pavitra Ramachandran
Head of Ocular *In Vivo* Translational Sciences
Sanofi



Kirsten Cummiskey
Senior Principal Engineer
Genentech



Fernando Correa
Executive Director
Kodiak Sciences



Ajit D'Souza
Executive Director, Drug Delivery & Devices
Eli Lilly & Co.

Proud to Partner With:

helbling

NOXILIZER

www.ophthalmic-drug-delivery.com
T +1 617 455 4188 **E** info@hansonwade.com

hansonwade

Welcome to the 5th Ophthalmic Drug Delivery Summit



Ophthalmic drug delivery is reaching a critical inflection point, with growing clinical validation, regulatory progress and late-stage successes from organizations such as **Tenpoint Therapeutics** and **Ocular Therapeutics** accelerating investment and innovation, while longstanding challenges around ocular barriers, poor bioavailability, frequent injections and treatment burden remain.

The **5th Ophthalmic Drug Delivery Summit** brings together the industry leaders developing the technologies and strategies needed to overcome these challenges. Hear practical insights from drug delivery and combination product experts at companies including **Genentech**, **Everads**, **Tarsus**, **Eli Lilly**, **Sanofi**, and **Astellas**, exploring advances across long-acting therapies, suprachoroidal delivery, implants, topical approaches and drug-device combinations.

Explore **Kodiak Sciences**' ABC platform, **Ripple Therapeutics'** Epidel sustained drug platform, **Re-Vana Therapeutics**' OcuLief technology and encapsulated cell therapy approaches from **Neurotech Pharmaceuticals** to benchmark the latest long-acting delivery technologies.

De-risk translation from preclinical to clinical success, learning how leaders from **Sanofi**, **Astellas**, **Apellis**, **Genentech**, and more are approaching animal-model selection, predictive endpoints, biomarkers, durability, safety and clinical translation

Unlock next-generation delivery routes, assessing the potential of **suprachoroidal**, **intravitreal**, **topical**, **implantable**, and **hydrogel-based** delivery to overcome ocular barriers, improve therapeutic exposure and reduce treatment burden

Connect with the full drug-delivery ecosystem as we bring together **Discovery**, **Clinical, Drug-Device/ Combination**, **Delivery**, **Engineering, Technology**, **CMC**, and **Formulation** leaders from across the ophthalmic biopharma landscape to build the collaborations needed to move promising technologies forward

"I enjoyed the variety of topics and presenters and also liked that the attendees represented diverse functions in the industry."

Associate Director Device Quality, **Merck**

2027 Presenting Companies Include:

Lilly · KODIAK · Genentech A Member of the Roche Group · astellas · sanofi · beacon therapeutics

www.ophthalmic-drug-delivery.com
T +1 617 455 4188 **E** info@hansonwade.com

hansonwade

Celebrating Five Years of Innovation in Ophthalmic Drug Delivery

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

To mark the summit's **5th anniversary**, we've introduced brand-new workshops, panels and expert-led discussions designed to address the industry's biggest challenges across funding, development, delivery technologies, translational science and regulatory strategy.

What's New?

01 Investor & Partner Readiness


Learn directly how leading investors and pharmaceutical partners evaluate ophthalmic opportunities and what separates fundable programs from those that struggle to secure support.

Gain practical insights into building stronger data packages, partnership strategies, and commercial narratives that resonate with decision-makers.

02 Making Long-Acting Therapies Work

Hear real-world lessons from **Eli Lilly**, **Genentech**, **Apellis** & **NeuParadigmBio** as they share what drives successful translation from preclinical promise to clinical impact.

Explore strategies to improve durability, manage development risk, and avoid common formulation and delivery challenges.



03 Validating Preclinical Models

Examine how leading teams such as **Sanofi** are selecting and validating animal models that generate more predictive data and support stronger development decisions.

Learn how better model selection can reduce timelines, improve translational confidence, and strengthen regulatory submissions.

04 Regulatory Lessons From Success & Setbacks

Benefit from firsthand regulatory perspectives with former FDA advisor **Maryam Mokhtarzadeh** on navigating approvals, avoiding common pitfalls, and preparing stronger submissions.

Understand how developers are addressing evolving expectations for novel modalities, including gene and cell therapies.

05 Next-Generation Delivery Technologies

Discover the latest advances shaping ocular delivery, from hydrogel platforms and suprachoroidal administration to device-drug integration and emerging gene therapy approaches.

Understand how delivery innovation is enabling more precise, durable, and patient-friendly treatments with updates from **Ripple**, **Re-Vana**, **GelMEDIX**, **Everads-Therapy**, **Genentech** and more!

www.ophthalmic-drug-delivery.com
T +1 617 455 4188 **E** info@hansonwade.com

hansonwade

Your Expert Speakers

Global Pharma Leaders



Ajay Khopade
Vice President, Head of Formulation Non-Orals & Analytical, & R&D Site Head
Sun Pharmaceutical Industries



Ajit D'Souza
Executive Director, Drug Delivery & Devices Ddcs
Eli Lilly & Co.



Hemant Khanna
Ophthalmology Strategy Lead
Astellas



Justin Creel
Executive Director - Device Development
Genentech



Kirsten Cummiskey
Senior Principal Engineer
Genentech



Pavitra Ramachandran
Head of Ocular *In Vivo* Translational Sciences
Sanofi

Biotech Innovators



Abraham Scaria
Chief Scientific Officer
Beacon Therapeutics




Cyndi Lee
Product Management
Re-Vana Therapeutics



Daniel Chao
Vice President & Head of Clinical Development
Surrozen



Fernando Correa
Executive Director
Kodiak Sciences



Ian McHugh
Process Engineer
Neurotech Pharmaceuticals



Juan Pablo Robles
Associate Researcher
National University of Mexico (UNAM)
Founder
VIAN Therapeutics



Max Cotler
Chief Executive Officer
GelMEDIX



Moshe Weinstein
Chief Executive Officer
Everads-Therapy



Patrick H. Ruane
Chief Operating Officer
Re-Vana Therapeutics



Raj Patil
Chief Scientific Officer
OKYO Pharma Ltd.



Stephen Poor
Head of Translational Medicine
Apellis



Viral Kansara
Chief Discovery & Development Advisor
NeuParadigmBio



Wendy Naimark
Chief Technology Officer & Co Founder
Ripple Therapeutics

Scientific Thought Leaders & Investors



Claire Gelfman
Associate Adjunct Professor
University of California, Irvine, Department of Ophthalmology & Vision Sciences



David Almeida
Vitreoretinal Surgeon-Scientist
Erie Retina Research



Maryam Mokhtarzadeh
Chief Medical Officer
Persephoni bio

Pre-Conference Workshop Day
Jaunary 19, 2027

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

Check-in, Coffee & Light Breakfast — 8.00

Workshop A — 9.00

Mastering Toxicology Strategy for Ophthalmic Products to Accelerate Path to the Clinic

Gain the critical insights needed to design toxicology programs that satisfy regulatory requirements while minimizing delays and costs. This collaborative workshop brings together toxicologists, regulatory experts, and preclinical specialists to help you navigate the complexities of safety assessment for novel ophthalmic delivery systems.

This workshop will gather experts to discuss:

- Master the selection of appropriate animal models (rabbits, non-human primates, mini pigs) and understand when each species provides the most predictive safety data for your specific formulation
- Learn how to structure GLP and non-GLP studies to de-risk your program, avoid costly FDA rejections, and determine the optimal timing for regulatory submission of your toxicology protocols
- Discover strategies to assess inflammation, immunogenicity, and ocular tissue damage for long-acting formulations, implants, and biologics while ensuring your safety package translates effectively to human trials

Workshop Leaders



Claire Gelfman
Associate Adjunct Professor
University of California, Irvine, Department of Ophthalmology & Vision Sciences

Morning Break & Networking — 11.00

Workshop B — 11.30

Integrating Formulation, Device, & Human Factors from Day One to Build Winning Cross-Functional Teams

Transform your development timeline by learning how leading companies align formulation scientists, device engineers, and human factors specialists from the earliest stages. This interactive roundtable helps you break down silos and establish collaborative workflows that prevent costly late-stage redesigns.

This workshop will gather experts to discuss:

- Understand which critical device and usability considerations must inform your formulation strategy from concept phase to ensure injectability, patient comfort, and clinical adoption
- Explore real-world case studies showing how early integration of CMC, sterilization requirements, and manufacturing constraints saves time and capital while improving product performance
- Develop actionable frameworks for bringing clinician perspectives into your design process, ensuring your product fits seamlessly into retinal specialist workflows and maximizes market acceptance

Workshop Leaders



Cyndi Lee
Program Management
Re-Vana Therapeutics

Lunch Break & Networking — 1.30

Pre-Conference Workshop Day
Jaunary 19, 2027

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

Workshop C 2.30

Understanding What Investors & Pharma Partners Want to See in Ophthalmic Programs

This workshop aims to bring together venture investors and pharmaceutical partnering leaders to provide practical guidance on building compelling investment packages and partnership opportunities. Navigate today's challenging funding landscape by understanding exactly what venture capitalists and pharmaceutical partners evaluate when considering ophthalmic drug delivery investments.

This workshop will gather experts to discuss:

- Learn what data packages, intellectual property positions, and team capabilities pharma partners require for early-stage deals, including insights from companies that have secured partnerships before entering the clinic
- Discover how to position your program to attract investment in an environment where mega-rounds dominate and capital for smaller raises is increasingly scarce
- Gain strategies for demonstrating your technology's commercial viability, addressing reimbursement considerations, and articulating clear paths to market that resonate with both investors and strategic partners

Workshop Leaders



Maryam Mokhtarzadeh
Chief Medical Officer
Persephoni bio



Wendy Naimark
Chief Technology Officer & Co Founder
Ripple Therapeutics

End of Pre-Conference Workshop Day 4.30

"High quality presentations. Efficient running of the conference."

Chief Scientific Officer, NanOptima

"The networking opportunities offered offered by this conference were exceptional. I appreciated the focused program which brings professionals in the field together, which made it easy to engage in conversations and build relationships after the talks."

Executive Director, Protein Sciences & Structural Biology, Frontier Medicines

Conference Day One
January 20, 2027

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

7:30 Check In, Coffee & Light Breakfast

8.20 Chair's Opening Remarks



Ajit D'Souza
Executive Director, Drug Delivery & Devices
Eli Lilly

Extending Biologic Durability To Reduce Treatment Burden & Improve Patient Outcomes

8:30 **From Molecular Design to Clinical Durability: Extending Ocular Half-Life with the Antibody Biopolymer Conjugate (ABC) Platform**

- Explore how the ABC Platform increases molecular size and extends ocular residence time
- Review clinical evidence linking tarcocimab's approximately 20-day ocular half-life to durable disease control and longer dosing intervals
- Discover how the Antibody Biopolymer Conjugate Drug (ABCD) Platform extends ABC into a modular system for the tailored delivery of diverse drug cargos and durable multi-mechanism therapies



Fernando Correa
Executive Director
Kodiak Sciences

9:00 Session Reserved helbling

9.30 **Ripple's Epidel Sustained Drug Platform: From Discovery to the Clinic**

- Discovery of the Epidel prodrug technology, and the systematic evaluation process that identified ophthalmology
- Building an ophthalmology-focused team from the ground up
- Generating preclinical and clinical proof-of-concept data sets robust enough to secure capital and anchor strategic partnerships
- Advancing proprietary pipeline programs in parallel with partnered development programs, sustaining internal innovation alongside strategic collaboration



Wendy Naimark
Chief Technology Officer & Co founder
Ripple Therapeutics

10.00 Speed Networking
A dedicated networking opportunity designed to connect the ophthalmic drug delivery community. Exchange insights with experts across drug development, delivery, formulation, devices, and translational sciences, and discuss the scientific, clinical, and commercial challenges driving innovation in ocular therapeutics.



10.30 Morning Break & Refreshments

Extending Therapeutic Effect with Long-Acting Retinal Therapies & Enhanced Delivery Systems

11:00 **Harnessing OcuLief Technology to Improve Retinal Drug Durability, Reduce Treatment Burden & Enhance Patient Outcomes**

- Explore how Re-Vana's OcuLief technology enables a high-payload liquid formulation to be delivered through a conventional intravitreal injection and rapidly transformed into a solid implant using visible light, providing sustained drug release directly within the eye
- Understand how OcuLief is designed to overcome the limitations of frequent intravitreal injections by extending therapeutic durability, maintaining local drug exposure, and supporting improved patient adherence in retinal disease management
- Assess the clinical, manufacturing, and regulatory considerations associated with translating light-activated sustained-release implants into practice and discover what is required to achieve broad clinical adoption and commercial success in ophthalmology



Patrick Ruane
Chief Operating Officer
Re-Vana Therapeutics

11.30 Session Reserved NOXILIZER™

Conference Day One
January 20, 2027

12:00 **Panel Discussion: Improving Long-Acting Therapy Success Rates Through Real-World Lessons in Durability, Translation & Development**

- Join experienced developers and researchers of long-acting ocular therapies to explore lessons from ongoing development to avoid common pitfalls and accelerate development
- Understand why promising durability data often fails to translate from preclinical studies into clinical success and learn how to generate more predictive evidence earlier in development
- Learn how to overcome formulation, delivery, inflammation, and safety challenges while improving durability, efficacy, and patient experience
- Discuss practical strategies for managing development risk, investment timelines, and key decision points to improve long-term clinical and commercial success



Ajit D'Souza
Executive Director, Drug Delivery & Devices
Eli Lilly



Stephen Poor
Head of Translational Medicine
Apellis



Justin Creel
Executive Director, Device Development
Genentech



Viral Kansara
Chief Discovery & Development Advisor
NeuParadigmBio

12.45 **Lunch & Networking Break**

Enabling Successful Ocular Therapy Delivery Through Device Advancements & Drug Product Integration

1:45 **Advancing Suprachoroidal Delivery Through Real-World Lessons, Emerging Technologies & Clinical Experience**

- Learn from the evolution of suprachoroidal delivery and understand the key breakthroughs that are expanding its potential across gene therapies and retinal therapeutics
- Evaluate the strengths, limitations, and development considerations of emerging suprachoroidal delivery technologies to accelerate program success and avoid common pitfalls
- Gain practical insights from preclinical and clinical experience on optimising dose, volume, delivery technique, and target engagement to improve outcomes and reduce development risk



Moshe Weinstein
Executive Chairman
Everads-Therapy

2:15 **Leveraging Hydrogel Delivery Technologies to Improve Cell Therapy Engraftment & Retinal Regeneration**

- Examine how injectable hydrogel scaffolds can protect therapeutic cells during administration, improve retention at the target site, and enhance long-term functional integration
- Understand the practical considerations involved in selecting surgical delivery devices, designing translational studies, and generating the evidence needed to support regulatory approval
- Explore how hydrogel platforms are being adapted for cell therapies, gene therapies, and other advanced modalities to improve efficacy, safety, and clinical adoption



Max Cotler
Chief Executive Officer
GelMEDIX

2.45 **Engineering Precision Delivery: Integrating Device Engineering, Preclinical Modeling, & Molecule Development for Efficient Therapeutic Selection**

- Understand how developing species-specific delivery to reliably target the tissue of interest improves therapeutic down selection
- See how our team has modified our clinical devices for preclinical anatomy, how we evaluate the designs, and what cross-functional subject matter experts should be included
- Learn how subretinal delivery of AAV gene therapy via alternative routes effects ocular inflammatory profiles



Kirsten Cummiskey
Senior Principal Engineer
Genentech

Conference Day One
January 20, 2027

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

3:15 **Afternoon Break & Poster Session**
Join an engaging poster session designed to encourage meaningful conversations, collaboration, and knowledge exchange in a relaxed setting. Explore innovative presentations in ophthalmic drug delivery and showcase your research and developments. Connect with experts, discover new insights, and share your work with the community.



4:15 **Encapsulated Cell Technology: Versatile, Tunable, Durable**

- Encapsulated Cell Technology (ECT) allows for long-term delivery of therapeutics
- ECT devices are functional after ocular implantation for at least 15 years
- A wide range of therapeutics, from small peptides to antibody fragments, are deliverable from ECT devices



Ian McHugh
Process Engineer
Neurotech Pharmaceuticals

Navigating Regulatory Pathways & Clinical Development to Accelerate Ophthalmic Product Approval

4:45 **Roundtable Discussion: Accelerating Regulatory Approval by Applying Lessons from Successful & Challenged Ophthalmic Programs**

- Learn directly from developers who have navigated approvals, regulatory delays, and setbacks to identify the strategies that improve submission success and reduce risk
- Understand common reasons for complete response letters and how to proactively address these issues in your development plan
- Discuss emerging regulatory considerations for novel modalities including gene therapies, cell therapies, and extended-release implants where precedents are still being established





Maryam Mokhtarzadeh
Chief Medical Officer
Persephoni bio

5:15 **Building More Predictive Preclinical Strategies for Successful Clinical Translation**

- Discuss the importance of preclinical model selection and data quality in improving translation from preclinical studies to human trials
- Explore how endpoint selection should be scientifically driven by the chosen preclinical model and aligned with clinically relevant features of the human disease
- Examine how preclinical readouts can be evaluated for their relevance and predictive value in human trials, helping identify models with greater translational potential



Raj Patil
Chief Scientific Officer
OKYO Pharma

5:45 **Chair's Closing Remarks**

5:50 **End of Day One**

"Excellent line-up of industry experts. Very engaging and innovative content."

Senior Manager, R&D Engineering Team Leader,
Teva Pharmaceuticals

Conference Day Two
January 21, 2027

7:30 Check In, Coffee & Light Breakfast

8:20 **Chair's Opening Remarks**



Viral Kansara
Chief Discovery & Development Advisor
NeuParadigmBio

Advancing Retinal Gene Therapies Through Improved Delivery & Clinical Translation

8:30 **Selecting Optimal Gene Therapy Delivery Strategy to Maximise Efficacy, Safety & Patient Reach**

- Compare intravitreal AAV delivery for secreted proteins versus subretinal surgery for intracellular targets, understanding which retinal cell populations each route can effectively transduce
- Explore emerging suprachoroidal gene therapy delivery that may offer a middle ground between surgical complexity and transduction efficiency for RPE and photoreceptor targets
- Evaluate novel capsid engineering strategies that enable efficient transduction from the vitreous while minimizing dose-dependent inflammation



Abraham Scaria
Chief Scientific Officer
Beacon Therapeutics

9:00 **Bridging the Translation Gap in Retinal Gene & Cell Therapy: Delivery Strategies, Biomarkers, & Predictive Development Models**

- Accelerating translation from preclinical research to clinical success with more predictive development strategies
- Optimizing retinal delivery strategies
- Building commercially viable retinal gene and cell therapies
- Reducing development risk through improved translational science



Hemant Khanna
Ophthalmology Strategy Lead
Astellas

9.30 Morning Break & Networking

Optimising Clinical Development Through Better Endpoints, Physician Insights & Patient Engagement

10.30 **Did the Drug Get There, & Did It Work? Verifying Target Access, Drug Engagement & Clinical Translation in Ophthalmic Drug Delivery**

- Showcase proving placement with the Near-Real Surgical Specimens (NRSS), a reperfused human ocular tissue platform, as the true human analog for testing delivery devices, with real-time OCT and contrast visualization of suprachoroidal access (inter-specimen CV 6.8% vs 17.7% in cadaveric eyes; TVST 2025)
- Demonstrate accelerated from bench to investigator translation and how the same platform trains and certifies trial PIs on suprachoroidal gene-therapy injection (ICG confirmation of the space) and de-risks first-in-human studies across multiple sponsor programs
- Introduce TEMPO tear proteomics from a Schirmer strip as a non-invasive pharmacodynamic readout, ~3,000 proteins, quantified receptor-pathway inhibition and washout after an IGF-1R biologic in thyroid eye disease, and what this means for precision dosing and payer evidence



David Almeida
Vitreoretinal Surgeon-Scientist
Erie Retina Research

Conference Day Two
January 21, 2027

11.00 **Panel Discussion: How Can We Improve Clinical Translation by Bridging the Gap Between Preclinical & Human Studies**

- Discuss common causes of translational disconnect in efficacy, durability, safety, and immunogenicity from preclnical studies to humans
- Compare the strengths and limitations of rodent, rabbit, minipig, and nonhuman primate models for disease modeling, PK/PD characterization, biodistribution, and safety assessment.
- Discuss the potential of organoids, microphysiological systems, *ex vivo* human ocular tissues, and computational modeling to complement or replace traditional animal studies.
- Discuss common deficiencies, evidence gaps, or study design limitations that lead to regulatory questions, delays, or clinical holds for preclinical IND packages



Daniel Chao
Vice President & Head of Clinical Development
Surrozen



David Almeida
Vitreoretinal Surgeon-Scientist
Erie Retina Research



Pavitra Ramachandran
Head of Ocular *In Vivo* Translational Sciences
Sanofi

11.45 **Lunch & Networking Break**

Strengthening Clinical Confidence Through Translational Science & Preclinical Strategy

12.45 **Selecting & Validating Animal Models for Ophthalmic Drug Delivery**

- Discuss how to select the most predictive animal models for your delivery route, formulation, and indication by understanding the strengths and limitations of rabbit, non-human primate, and minipig studies
- Determine when disease models provide meaningful pharmacodynamic insights
- Reduce development timelines, costs, and regulatory risk through strategic non-GLP and GLP study planning that supports stronger IND submissions



Pavitra Ramachandran
Head of Ocular *In Vivo* Translational Sciences
Sanofi

1.15 **Roundtable Discussion: Proving Long-Term Therapeutic Value Through Endpoint Selection & Clinical Trial Design**

Join breakout roundtables led by expert moderators to debate key questions, capture consensus and differing views, then reconvene as moderators share insights and spark wider audience debate.

- Discuss how the field should evolve beyond traditional visual acuity measures by identifying functional endpoints that better reflect real-world patient experience, including contrast sensitivity, low-light vision, and other measures of meaningful visual function
- Share experiences validating novel endpoints with regulatory agencies, exploring the evidence packages, study designs, and clinical data required to support acceptance of new outcome measures in future retinal trials
- Explore how predictive biomarkers, advanced imaging analytics, and emerging endpoint strategies can improve patient selection, accelerate development timelines, and generate stronger evidence for regulatory approval and long-term therapeutic value
- Debate which functional endpoints should be prioritised in future retinal studies, how they should be implemented within clinical trials, and what level of change represents a clinically meaningful benefit for patients





Stephen Poor
Head of Translational Medicine
Apellis

2.00 **Afternoon Break & Networking**

Conference Day Two
January 21, 2027

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

Defining the Future of Ophthalmic Drug Delivery With Novel Technology

2.30 **Advancing Topical Retinal Drug Delivery to Reduce Treatment Burden & Expand Global Access**

- Understand how to overcome the biological barriers that have historically limited topical drug delivery to the retina and unlock new opportunities for non-invasive treatment
- Explore formulation strategies that improve retinal penetration and therapeutic activity while maintaining ocular safety and tolerability, and enable convenient dosing to enhance adherence and long-term treatment success
- Learn how next-generation topical therapies could reduce reliance on intravitreal injections while expanding access to retinal disease treatment for underserved patient populations worldwide



Juan Pablo Robles
Associate Researcher
National University of Mexico (UNAM)
Founder
VIAN Therapeutics

3.00 **Lifecycle Extension Through Ophthalmic Drug Delivery Innovation via Reformulation & Repurposing of drug molecules**

- Drug Delivery as a Product Life-Cycle Strategy: Leveraging advanced drug delivery technologies to enhance patient convenience and compliance, improve safety and efficacy, expand therapeutic applications, and maximize product value
- Successful Case Studies from Sun Pharma R&D: Showcasing innovative drug delivery platforms that have successfully navigated complex formulation development, clinical evaluation, and regulatory pathways to achieve commercialization
- From Innovation to Market Success: Highlighting the key scientific, technical, regulatory, and strategic considerations required to translate drug delivery concepts into commercially viable products with meaningful value for patients and healthcare systems



Ajay Khopade
Vice President, Head of Formulation Non-Orals & Analytical, & R&D Site Head
Sun Pharmaceutical Industries

3.30 **Looking Ahead to The Future of Ophthalmic Drug Delivery**

- The Next Generation of Long-Acting Ocular Delivery: Next-generation targeted and minimally invasive delivery systems beyond Intravitreal Injections to extend ocular exposure and reduce treatment burden
- Precision and Repeatable Office-Based Therapy: Advancing non-viral vectors, ASOs, siRNA, and other platforms for precise, durable, and potentially repeatable ocular therapies
- Engineering Exposure, Not Just Dose: Integrating tissue targeting, PK/PD, biomarkers, and digital twins to optimize ocular exposure, therapeutic windows, and patient selection
- AI-Powered Drug Delivery: Leveraging AI to design delivery systems, predict tissue exposure, optimize formulations, and enable more personalized ocular therapies



Viral Kansara
Chief Discovery & Development Advisor
NeuParadigmBio

4.00 **Chair's Closing Remarks**



Viral Kansara
Chief Discovery & Development Advisor
NeuParadigmBio

4.10 **End of Conference**

2027 Partners

Expertise Partner: Helbling Technik Bern

Helbling Technik is part of the Helbling Group and functions as a long-term partner in its customers innovation network, under the motto “Innovation, together we do it”. The company’s engineers use high-performance tools and infrastructures, and high-quality professional approaches to generate new ideas, implement state-of-the-art technologies and develop successful new products. With our systems engineering and development capabilities, we make your vision real for Combination Products, Connected Devices, Surgical Instruments and Active Implants.

www.helbling.ch

Innovation Partner: Noxilizer

Noxilizer provides ultra-low temperature nitrogen dioxide (NO_2) terminal sterilization for the pharmaceutical, biotechnology, and medical device industries. With FDA approvals and clearance, EMA authorization, and adoption by leading global manufacturers, Noxilizer’s NO_2 sterilization is a safe, efficient, and scalable alternative to existing methods. The company offers R&D studies, packaging and design consulting, validation and customer and technical support in addition to its proprietary sterilization equipment and consumables.

www.noxilizer.com

“It was great to connect with different people with different expertise. The event was well managed and very enjoyable.”

Head of Business Unit, **Helbling**



Contact

Eirini Karavasili - Partnerships Director
Email: sponsor@hansonwade.com
Tel: +1 617 455 4188

Put Your Brand at the Heart of Ophthalmic Drug Delivery

5th Annual Ophthalmic Drug Delivery Summit
January 19-21, 2027 | San Francisco, CA

Your Platform to Connect, Influence & Generate Opportunities Across the Evolving Ophthalmic Drug Delivery Landscape

Raise Your Profile Among Key Industry Decision-Makers

Access a highly targeted community of professionals actively evaluating new technologies, solutions and partnerships across ophthalmic drug delivery. Engage with decision-makers from pharma, biotech, academia and investment, and make your organization part of the conversations shaping the next generation of ocular therapeutics, with 9 C-level executives on the speaking faculty alone!


Showcase Your Expertise & Differentiate Your Solutions

Put your technology, services and solutions at the centre of conversations tackling the industry's biggest delivery challenges. With dedicated sessions spanning long-acting therapies, suprachoroidal delivery, implants, topical delivery, drug-device integration, gene and cell therapy and translational science, demonstrate where your capabilities can make a difference.

Build Relationships That Drive Commercial Growth

Go beyond visibility and engage directly with potential partners, customers and collaborators through speed networking and dedicated breaks, poster sessions, workshops and interactive discussions. Build relationships across the ocular ecosystem, uncover emerging requirements and identify new opportunities for collaboration, partnerships and growth.


Seniority of Attendees*



- CXO – 22%
- President/VP – 20%
- Director/Head – 36%
- Manager – 10%
- Other – 12%

*Audience Breakdown taken from the 4th Ophthalmic Drug Delivery Summit

Type of Companies Attending*



- Drug Developers – 54%
- Technology/Equipment Providers – 26%
- Service Providers – 15%
- Academics, Research Institutes & Other – 5%



Contact

Eirini Karavasili - Partnerships Director
Email: sponsor@hansonwade.com
Tel: +1 617 455 4188

www.ophthalmic-drug-delivery.com

T +1 617 455 4188 **E** info@hansonwade.com

hansonwade

Ready to Register?

3 Easy Ways To Book

www.ophthalmic-drug-delivery.com/register/

info@hansonwade.com

+1 617 455 4188

Discover the latest advances transforming ophthalmic drug delivery, from long-acting and implantable systems to suprachoroidal, topical and next-generation delivery technologies. Hear how leading companies including **Genentech**, **Kodiak Sciences**, **Ripple Therapeutics**, **Re-Vana Therapeutics** and **Everads** are tackling the challenges of durability, targeting and treatment burden

De-Risk your development strategy with practical insights from leaders across the drug-delivery ecosystem. Explore real-world approaches to preclinical translation, toxicology, regulatory pathways, formulation, device integration, manufacturing and clinical development, helping you identify potential challenges earlier and accelerate the path to success

Connect with the people shaping the future of ocular therapeutics. Build valuable relationships across pharma, biotech, academia and investment, to exchange ideas, uncover new opportunities and find the partnerships needed to move your programs forward

Industry Pricing*	Register & Pay by Friday October 30	On the Door
Conference + Workshop Day	$3,707 **(Save $900)**	$4,607
Conference Only	$2,749 **(Save $400)**	$3,149
Academic Pricing**	**Register & Pay by Friday October 30**	**On the Door**
Conference + Workshop Day	$3,107 **(Save $900)**	$4,007
Conference Only	$2,349 **(Save $400)**	$2,749
Service Provider Pricing***	**Register & Pay by Friday October 30**	**On the Door**
Conference + Workshop Day	$4,707 **(Save $250)**	$4,957
Conference Only	$3,449 **(Save $250)**	$3,699

* To be eligible for this price, the group or individuals must be from a biotech or pharma company that has a publicly available pipeline, and does not offer pay for services.
** To be eligible for this price, the group or individual must be full-time academic(s).
*** If you are a solution or service provider, have you considered sponsoring this event? Sponsorship includes multiple passes at a discounted rate. Inquire to learn more.

Multi-Pass Discounts

10% discount 2 passes

15% discount 3 passes

20% discount 4+ passes

Please note that group discounts are only valid when two or more delegates from one company book and pay at the same time. Only one discount offer may be applied to the current pricing rate. Contact: register@hansonwade.com

VENUE:

Hyatt Centric Fisherman Wharf

555 North Point St, San Francisco, CA 94133

www.hyatt.com/hyatt-centric/en-US/sfofw-hyatt-centric-fishermans-wharf



Terms & Conditions
Full payment is due on registration.

Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda:
Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Ltd. is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Ltd., Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH